APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurodegenerative Drugs Market Analysis and Forecast 2026-2032

19 December 2025203 pages

Choose your research edition.

Industry ResearchNeurodegenerative Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neurodegenerative Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neurodegenerative Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurodegenerative Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurodegenerative Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neurodegenerative Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurodegenerative Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Neurodegenerative Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurodegenerative Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neurodegenerative Drugs sales, projected growth trends, production technology, application and end-user industry.

Neurodegenerative Drugs Segment by Company

TEVA

Sanofi

Novartis

Luye Pharma

Livzon Pharmaceutical

Kanghong Pharmaceutical

Jingxin Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hisun Pharmaceutical

Haisco Pharmaceutical

GlaxoSmithKline

Ark Pharmaceutical

Dongcheng Biochemicals

BORA PHARMACEUTICALS

UCB

Merck Serono

Boehringer Ingelheim

Biogen Idec

Neurodegenerative Drugs Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Drugs Segment by Application

Parkinson’s Disease

Amyotrophic Lateral Sclerosis

Huntington Disease

Alzheimer’s Disease

Neurodegenerative Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neurodegenerative Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NMDA Major Manufacturers Table 3. SSRIs Major Manufacturers Table 4. Dopamine Inhibitors Major Manufacturers Table 5. Global Neurodegenerative Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Parkinson’s Disease Major Manufacturers Table 7. Amyotrophic Lateral Sclerosis Major Manufacturers Table 8. Huntington Disease Major Manufacturers Table 9. Alzheimer’s Disease Major Manufacturers Table 10. Neurodegenerative Drugs Industry Trends Table 11. Neurodegenerative Drugs Industry Drivers Table 12. Neurodegenerative Drugs Industry Opportunities and Challenges Table 13. Neurodegenerative Drugs Industry Restraints Table 14. Global Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Neurodegenerative Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Neurodegenerative Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Neurodegenerative Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Neurodegenerative Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 20. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (Tons) Table 21. Global Neurodegenerative Drugs Sales by Region (2027-2032) & (Tons) Table 22. Global Neurodegenerative Drugs Sales Market Share by Region (2021-2026) Table 23. Global Neurodegenerative Drugs Sales Market Share by Region (2027-2032) Table 24. Global Neurodegenerative Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Neurodegenerative Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Neurodegenerative Drugs Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 29. Global Neurodegenerative Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Neurodegenerative Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Neurodegenerative Drugs Manufacturers, Product Type & Application Table 32. Global Neurodegenerative Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Neurodegenerative Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Neurodegenerative Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Neurodegenerative Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Neurodegenerative Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 41. Global Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 42. Global Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 43. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2026) Table 44. Global Neurodegenerative Drugs Sales Market Share by Type (2027-2032) Table 45. Global Neurodegenerative Drugs Price by Type (2021-2026) & (US$/Ton) Table 46. Global Neurodegenerative Drugs Price by Type (2027-2032) & (US$/Ton) Table 47. Global Neurodegenerative Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Neurodegenerative Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Neurodegenerative Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 53. Global Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 54. Global Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 55. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2026) Table 56. Global Neurodegenerative Drugs Sales Market Share by Application (2027-2032) Table 57. Global Neurodegenerative Drugs Price by Application (2021-2026) & (US$/Ton) Table 58. Global Neurodegenerative Drugs Price by Application (2027-2032) & (US$/Ton) Table 59. TEVA Company Information Table 60. TEVA Business Overview Table 61. TEVA Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 62. TEVA Neurodegenerative Drugs Product Portfolio Table 63. TEVA Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Sanofi Neurodegenerative Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. Novartis Neurodegenerative Drugs Product Portfolio Table 73. Novartis Recent Development Table 74. Luye Pharma Company Information Table 75. Luye Pharma Business Overview Table 76. Luye Pharma Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Luye Pharma Neurodegenerative Drugs Product Portfolio Table 78. Luye Pharma Recent Development Table 79. Livzon Pharmaceutical Company Information Table 80. Livzon Pharmaceutical Business Overview Table 81. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 83. Livzon Pharmaceutical Recent Development Table 84. Kanghong Pharmaceutical Company Information Table 85. Kanghong Pharmaceutical Business Overview Table 86. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 88. Kanghong Pharmaceutical Recent Development Table 89. Jingxin Pharmaceutical Company Information Table 90. Jingxin Pharmaceutical Business Overview Table 91. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 93. Jingxin Pharmaceutical Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Pfizer Neurodegenerative Drugs Product Portfolio Table 98. Pfizer Recent Development Table 99. Huahai Pharmaceutical Company Information Table 100. Huahai Pharmaceutical Business Overview Table 101. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 103. Huahai Pharmaceutical Recent Development Table 104. Hisun Pharmaceutical Company Information Table 105. Hisun Pharmaceutical Business Overview Table 106. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 108. Hisun Pharmaceutical Recent Development Table 109. Haisco Pharmaceutical Company Information Table 110. Haisco Pharmaceutical Business Overview Table 111. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 113. Haisco Pharmaceutical Recent Development Table 114. GlaxoSmithKline Company Information Table 115. GlaxoSmithKline Business Overview Table 116. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 117. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio Table 118. GlaxoSmithKline Recent Development Table 119. Ark Pharmaceutical Company Information Table 120. Ark Pharmaceutical Business Overview Table 121. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 122. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 123. Ark Pharmaceutical Recent Development Table 124. Dongcheng Biochemicals Company Information Table 125. Dongcheng Biochemicals Business Overview Table 126. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 127. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio Table 128. Dongcheng Biochemicals Recent Development Table 129. BORA PHARMACEUTICALS Company Information Table 130. BORA PHARMACEUTICALS Business Overview Table 131. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 132. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio Table 133. BORA PHARMACEUTICALS Recent Development Table 134. UCB Company Information Table 135. UCB Business Overview Table 136. UCB Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 137. UCB Neurodegenerative Drugs Product Portfolio Table 138. UCB Recent Development Table 139. Merck Serono Company Information Table 140. Merck Serono Business Overview Table 141. Merck Serono Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 142. Merck Serono Neurodegenerative Drugs Product Portfolio Table 143. Merck Serono Recent Development Table 144. Boehringer Ingelheim Company Information Table 145. Boehringer Ingelheim Business Overview Table 146. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 147. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio Table 148. Boehringer Ingelheim Recent Development Table 149. Biogen Idec Company Information Table 150. Biogen Idec Business Overview Table 151. Biogen Idec Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 152. Biogen Idec Neurodegenerative Drugs Product Portfolio Table 153. Biogen Idec Recent Development Table 154. North America Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 155. North America Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 156. North America Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 157. North America Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 158. North America Neurodegenerative Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 159. North America Neurodegenerative Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 160. North America Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 161. North America Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 162. North America Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 163. North America Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 164. North America Neurodegenerative Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 165. North America Neurodegenerative Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 166. North America Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. North America Neurodegenerative Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 168. North America Neurodegenerative Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 169. North America Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 170. North America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 171. North America Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 172. North America Neurodegenerative Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 173. North America Neurodegenerative Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 174. United States Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 175. Canada Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 176. Europe Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 177. Europe Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 178. Europe Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 179. Europe Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 180. Europe Neurodegenerative Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 181. Europe Neurodegenerative Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 182. Europe Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 183. Europe Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 184. Europe Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 185. Europe Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 186. Europe Neurodegenerative Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 187. Europe Neurodegenerative Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 188. Europe Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 189. Europe Neurodegenerative Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 190. Europe Neurodegenerative Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 191. Europe Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 192. Europe Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 193. Europe Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 194. Europe Neurodegenerative Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 195. Europe Neurodegenerative Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 196. Germany Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 197. France Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 198. U.K. Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 199. Italy Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 200. Netherlands Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 201. Nordic Countries Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 202. China Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 203. China Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 204. China Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 205. China Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 206. China Neurodegenerative Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 207. China Neurodegenerative Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 208. China Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 209. China Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 210. China Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 211. China Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 212. China Neurodegenerative Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 213. China Neurodegenerative Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 214. Asia Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 215. Asia Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 216. Asia Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 217. Asia Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 218. Asia Neurodegenerative Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 219. Asia Neurodegenerative Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 220. Asia Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 221. Asia Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 222. Asia Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 223. Asia Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 224. Asia Neurodegenerative Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 225. Asia Neurodegenerative Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 226. Asia Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. Asia Neurodegenerative Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. Asia Neurodegenerative Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. Asia Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 230. Asia Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 231. Asia Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 232. Asia Neurodegenerative Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 233. Asia Neurodegenerative Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 234. Japan Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 235. South Korea Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 236. India Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 237. Australia Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 238. China Taiwan Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 239. Southeast Asia Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 240. SAMEA Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 241. SAMEA Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 242. SAMEA Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 243. SAMEA Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 244. SAMEA Neurodegenerative Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 245. SAMEA Neurodegenerative Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 246. SAMEA Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 247. SAMEA Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 248. SAMEA Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 249. SAMEA Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 250. SAMEA Neurodegenerative Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 251. SAMEA Neurodegenerative Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 252. SAMEA Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 253. SAMEA Neurodegenerative Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 254. SAMEA Neurodegenerative Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 255. SAMEA Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 256. SAMEA Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 257. SAMEA Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 258. SAMEA Neurodegenerative Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 259. SAMEA Neurodegenerative Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 260. Brazil Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 261. Argentina Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 262. Chile Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 263. Colombia Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 264. Peru Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 265. Saudi Arabia Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 266. Israel Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 267. UAE Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 268. Turkey Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 269. Iran Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 270. Egypt Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. Neurodegenerative Drugs Distributors List Table 274. Neurodegenerative Drugs Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. Neurodegenerative Drugs Image Figure 2. Global Neurodegenerative Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. NMDA Image Figure 5. SSRIs Image Figure 6. Dopamine Inhibitors Image Figure 7. Global Neurodegenerative Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neurodegenerative Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Parkinson’s Disease Image Figure 10. Amyotrophic Lateral Sclerosis Image Figure 11. Huntington Disease Image Figure 12. Alzheimer’s Disease Image Figure 13. Global Neurodegenerative Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Neurodegenerative Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Neurodegenerative Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Neurodegenerative Drugs Sales (2021-2032) & (Tons) Figure 19. Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 20. Global Neurodegenerative Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Neurodegenerative Drugs Sales YoY (2021-2032) & (Tons) Figure 22. Europe Neurodegenerative Drugs Sales YoY (2021-2032) & (Tons) Figure 23. China Neurodegenerative Drugs Sales YoY (2021-2032) & (Tons) Figure 24. Asia (Excluding China) Neurodegenerative Drugs Sales YoY (2021-2032) & (Tons) Figure 25. South America, Middle East and Africa Neurodegenerative Drugs Sales YoY (2021-2032) & (Tons) Figure 26. Global Neurodegenerative Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Neurodegenerative Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Neurodegenerative Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Neurodegenerative Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Neurodegenerative Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 33. Global Neurodegenerative Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Neurodegenerative Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Neurodegenerative Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Neurodegenerative Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 39. Global Neurodegenerative Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Neurodegenerative Drugs Revenue Share by Type (2021-2032) Figure 42. North America Neurodegenerative Drugs Sales Share by Type (2021-2032) Figure 43. North America Neurodegenerative Drugs Revenue Share by Application (2021-2032) Figure 44. North America Neurodegenerative Drugs Sales Share by Application (2021-2032) Figure 45. North America Neurodegenerative Drugs Revenue Share by Country (2021-2032) Figure 46. North America Neurodegenerative Drugs Sales Share by Country (2021-2032) Figure 47. Europe Neurodegenerative Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Neurodegenerative Drugs Sales Share by Type (2021-2032) Figure 49. Europe Neurodegenerative Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Neurodegenerative Drugs Sales Share by Application (2021-2032) Figure 51. Europe Neurodegenerative Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Neurodegenerative Drugs Sales Share by Country (2021-2032) Figure 53. China Neurodegenerative Drugs Revenue Share by Type (2021-2032) Figure 54. China Neurodegenerative Drugs Sales Share by Type (2021-2032) Figure 55. China Neurodegenerative Drugs Revenue Share by Application (2021-2032) Figure 56. China Neurodegenerative Drugs Sales Share by Application (2021-2032) Figure 57. Asia Neurodegenerative Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Neurodegenerative Drugs Sales Share by Type (2021-2032) Figure 59. Asia Neurodegenerative Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Neurodegenerative Drugs Sales Share by Application (2021-2032) Figure 61. Asia Neurodegenerative Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Neurodegenerative Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Neurodegenerative Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Neurodegenerative Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Neurodegenerative Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Neurodegenerative Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Neurodegenerative Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Neurodegenerative Drugs Sales Share by Country (2021-2032) Figure 69. Neurodegenerative Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neurodegenerative Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Alzheimer’s Disease
Companies covered
  • TEVA
  • Sanofi
  • Novartis
  • Luye Pharma
  • Livzon Pharmaceutical
  • Kanghong Pharmaceutical
  • Jingxin Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hisun Pharmaceutical
  • Haisco Pharmaceutical
  • GlaxoSmithKline
  • Ark Pharmaceutical
  • Dongcheng Biochemicals
  • BORA PHARMACEUTICALS
  • UCB
  • Merck Serono
  • Boehringer Ingelheim
  • Biogen Idec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurodegenerative Drugs Market by Type
  3. 1.2.1 Global Neurodegenerative Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NMDA
  5. 1.2.3 SSRIs
  6. 1.2.4 Dopamine Inhibitors
  7. 1.3 Neurodegenerative Drugs Market by Application
  8. 1.3.1 Global Neurodegenerative Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Parkinson’s Disease
  10. 1.3.3 Amyotrophic Lateral Sclerosis
  11. 1.3.4 Huntington Disease
  12. 1.3.5 Alzheimer’s Disease
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neurodegenerative Drugs Market Dynamics
  1. 2.1 Neurodegenerative Drugs Industry Trends
  2. 2.2 Neurodegenerative Drugs Industry Drivers
  3. 2.3 Neurodegenerative Drugs Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neurodegenerative Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neurodegenerative Drugs Revenue by Region
  3. 3.2.1 Global Neurodegenerative Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurodegenerative Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Neurodegenerative Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neurodegenerative Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neurodegenerative Drugs Sales by Region
  9. 3.4.1 Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neurodegenerative Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Neurodegenerative Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Neurodegenerative Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neurodegenerative Drugs Revenue by Manufacturers
  2. 4.1.1 Global Neurodegenerative Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neurodegenerative Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurodegenerative Drugs Sales by Manufacturers
  6. 4.2.1 Global Neurodegenerative Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neurodegenerative Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neurodegenerative Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neurodegenerative Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neurodegenerative Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neurodegenerative Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Neurodegenerative Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neurodegenerative Drugs Market CR5 and HHI
  16. 4.8.2 2025 Neurodegenerative Drugs Tier 1, Tier 2, and Tier 3
5 Neurodegenerative Drugs Market by Type
  1. 5.1 Global Neurodegenerative Drugs Revenue by Type
  2. 5.1.1 Global Neurodegenerative Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neurodegenerative Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neurodegenerative Drugs Sales by Type
  6. 5.2.1 Global Neurodegenerative Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neurodegenerative Drugs Sales by Type (2021-2032) & (Tons)
  8. 5.2.3 Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neurodegenerative Drugs Price by Type
6 Neurodegenerative Drugs Market by Application
  1. 6.1 Global Neurodegenerative Drugs Revenue by Application
  2. 6.1.1 Global Neurodegenerative Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neurodegenerative Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neurodegenerative Drugs Sales by Application
  6. 6.2.1 Global Neurodegenerative Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neurodegenerative Drugs Sales by Application (2021-2032) & (Tons)
  8. 6.2.3 Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neurodegenerative Drugs Price by Application
7 Company Profiles
  1. 7.1 TEVA
  2. 7.1.1 TEVA Company Information
  3. 7.1.2 TEVA Business Overview
  4. 7.1.3 TEVA Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 TEVA Neurodegenerative Drugs Product Portfolio
  6. 7.1.5 TEVA Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Neurodegenerative Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Luye Pharma
  20. 7.4.1 Luye Pharma Company Information
  21. 7.4.2 Luye Pharma Business Overview
  22. 7.4.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
  24. 7.4.5 Luye Pharma Recent Developments
  25. 7.5 Livzon Pharmaceutical
  26. 7.5.1 Livzon Pharmaceutical Company Information
  27. 7.5.2 Livzon Pharmaceutical Business Overview
  28. 7.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
  30. 7.5.5 Livzon Pharmaceutical Recent Developments
  31. 7.6 Kanghong Pharmaceutical
  32. 7.6.1 Kanghong Pharmaceutical Company Information
  33. 7.6.2 Kanghong Pharmaceutical Business Overview
  34. 7.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
  36. 7.6.5 Kanghong Pharmaceutical Recent Developments
  37. 7.7 Jingxin Pharmaceutical
  38. 7.7.1 Jingxin Pharmaceutical Company Information
  39. 7.7.2 Jingxin Pharmaceutical Business Overview
  40. 7.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
  42. 7.7.5 Jingxin Pharmaceutical Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Huahai Pharmaceutical
  50. 7.9.1 Huahai Pharmaceutical Company Information
  51. 7.9.2 Huahai Pharmaceutical Business Overview
  52. 7.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
  54. 7.9.5 Huahai Pharmaceutical Recent Developments
  55. 7.10 Hisun Pharmaceutical
  56. 7.10.1 Hisun Pharmaceutical Company Information
  57. 7.10.2 Hisun Pharmaceutical Business Overview
  58. 7.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
  60. 7.10.5 Hisun Pharmaceutical Recent Developments
  61. 7.11 Haisco Pharmaceutical
  62. 7.11.1 Haisco Pharmaceutical Company Information
  63. 7.11.2 Haisco Pharmaceutical Business Overview
  64. 7.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
  66. 7.11.5 Haisco Pharmaceutical Recent Developments
  67. 7.12 GlaxoSmithKline
  68. 7.12.1 GlaxoSmithKline Company Information
  69. 7.12.2 GlaxoSmithKline Business Overview
  70. 7.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
  72. 7.12.5 GlaxoSmithKline Recent Developments
  73. 7.13 Ark Pharmaceutical
  74. 7.13.1 Ark Pharmaceutical Company Information
  75. 7.13.2 Ark Pharmaceutical Business Overview
  76. 7.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
  78. 7.13.5 Ark Pharmaceutical Recent Developments
  79. 7.14 Dongcheng Biochemicals
  80. 7.14.1 Dongcheng Biochemicals Company Information
  81. 7.14.2 Dongcheng Biochemicals Business Overview
  82. 7.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
  84. 7.14.5 Dongcheng Biochemicals Recent Developments
  85. 7.15 BORA PHARMACEUTICALS
  86. 7.15.1 BORA PHARMACEUTICALS Company Information
  87. 7.15.2 BORA PHARMACEUTICALS Business Overview
  88. 7.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
  90. 7.15.5 BORA PHARMACEUTICALS Recent Developments
  91. 7.16 UCB
  92. 7.16.1 UCB Company Information
  93. 7.16.2 UCB Business Overview
  94. 7.16.3 UCB Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 UCB Neurodegenerative Drugs Product Portfolio
  96. 7.16.5 UCB Recent Developments
  97. 7.17 Merck Serono
  98. 7.17.1 Merck Serono Company Information
  99. 7.17.2 Merck Serono Business Overview
  100. 7.17.3 Merck Serono Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
  102. 7.17.5 Merck Serono Recent Developments
  103. 7.18 Boehringer Ingelheim
  104. 7.18.1 Boehringer Ingelheim Company Information
  105. 7.18.2 Boehringer Ingelheim Business Overview
  106. 7.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
  108. 7.18.5 Boehringer Ingelheim Recent Developments
  109. 7.19 Biogen Idec
  110. 7.19.1 Biogen Idec Company Information
  111. 7.19.2 Biogen Idec Business Overview
  112. 7.19.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
  114. 7.19.5 Biogen Idec Recent Developments
8 North America
  1. 8.1 North America Neurodegenerative Drugs Market Size by Type
  2. 8.1.1 North America Neurodegenerative Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Neurodegenerative Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Neurodegenerative Drugs Price by Type (2021-2032)
  5. 8.2 North America Neurodegenerative Drugs Market Size by Application
  6. 8.2.1 North America Neurodegenerative Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Neurodegenerative Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Neurodegenerative Drugs Price by Application (2021-2032)
  9. 8.3 North America Neurodegenerative Drugs Market Size by Country
  10. 8.3.1 North America Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neurodegenerative Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Neurodegenerative Drugs Market Size by Type
  2. 9.1.1 Europe Neurodegenerative Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neurodegenerative Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Neurodegenerative Drugs Price by Type (2021-2032)
  5. 9.2 Europe Neurodegenerative Drugs Market Size by Application
  6. 9.2.1 Europe Neurodegenerative Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neurodegenerative Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Neurodegenerative Drugs Price by Application (2021-2032)
  9. 9.3 Europe Neurodegenerative Drugs Market Size by Country
  10. 9.3.1 Europe Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neurodegenerative Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Neurodegenerative Drugs Market Size by Type
  2. 10.1.1 China Neurodegenerative Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Neurodegenerative Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Neurodegenerative Drugs Price by Type (2021-2032)
  5. 10.2 China Neurodegenerative Drugs Market Size by Application
  6. 10.2.1 China Neurodegenerative Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Neurodegenerative Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Neurodegenerative Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurodegenerative Drugs Market Size by Type
  2. 11.1.1 Asia Neurodegenerative Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neurodegenerative Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Neurodegenerative Drugs Price by Type (2021-2032)
  5. 11.2 Asia Neurodegenerative Drugs Market Size by Application
  6. 11.2.1 Asia Neurodegenerative Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neurodegenerative Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Neurodegenerative Drugs Price by Application (2021-2032)
  9. 11.3 Asia Neurodegenerative Drugs Market Size by Country
  10. 11.3.1 Asia Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neurodegenerative Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurodegenerative Drugs Market Size by Type
  2. 12.1.1 SAMEA Neurodegenerative Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neurodegenerative Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neurodegenerative Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Neurodegenerative Drugs Market Size by Application
  6. 12.2.1 SAMEA Neurodegenerative Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neurodegenerative Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neurodegenerative Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Neurodegenerative Drugs Market Size by Country
  10. 12.3.1 SAMEA Neurodegenerative Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neurodegenerative Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neurodegenerative Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neurodegenerative Drugs Value Chain Analysis
  2. 13.1.1 Neurodegenerative Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neurodegenerative Drugs Production Mode & Process
  6. 13.2 Neurodegenerative Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neurodegenerative Drugs Distributors
  9. 13.2.3 Neurodegenerative Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst